Positive Phase III for Lundbeck/Biotie's nalmefene
This article was originally published in Scrip
Executive Summary
Lundbeck and Biotie Therapies have reported positive data from two out of three Phase III trials evaluating the alcohol dependence therapy candidate, nalmefene. The companies expect to submit a marketing authorisation application in Europe in the second half of this year pending successful completion of the third Phase III trial, a short-term efficacy study, for which data should be available in the second quarter.